Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. Karapetis CS, et al. Among authors: shapiro jd. N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385. N Engl J Med. 2008. PMID: 18946061 Free article. Clinical Trial.
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008.
Price TJ, Tebbutt NC, Karapetis CS, Segelov E, Pavlakis N, Cunningham D, Sobrero AF, Haller DG, Shapiro JD. Price TJ, et al. Among authors: shapiro jd. Clin Colorectal Cancer. 2010 Jan;9(1):8-14. doi: 10.3816/CCC.2010.n.001. Clin Colorectal Cancer. 2010. PMID: 20100683 Review.
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.
Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA; NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group. Karapetis CS, et al. Among authors: shapiro jd. Clin Cancer Res. 2014 Feb 1;20(3):744-53. doi: 10.1158/1078-0432.CCR-13-0606. Epub 2013 Nov 11. Clin Cancer Res. 2014. PMID: 24218517 Clinical Trial.
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.
Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O'Callaghan CJ, Zalcberg JR, Karapetis CS, Dobrovic A. Liu G, et al. Among authors: shapiro jd. Clin Cancer Res. 2016 May 15;22(10):2435-44. doi: 10.1158/1078-0432.CCR-15-0414. Clin Cancer Res. 2016. PMID: 27179112 Clinical Trial.
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.
Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y, Tebbutt NC, Markman B, Price T, Esaki T, Koski S, Hitron M, Li W, Li Y, Magoski NM, Li CJ, Simes J, Tu D, O'Callaghan CJ. Jonker DJ, et al. Lancet Gastroenterol Hepatol. 2018 Apr;3(4):263-270. doi: 10.1016/S2468-1253(18)30009-8. Epub 2018 Feb 1. Lancet Gastroenterol Hepatol. 2018. PMID: 29397354 Clinical Trial.
Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.
Vickers MM, Karapetis CS, Tu D, O'Callaghan CJ, Price TJ, Tebbutt NC, Van Hazel G, Shapiro JD, Pavlakis N, Gibbs P, Blondal J, Lee U, Meharchand JM, Burkes RL, Rubin SH, Simes J, Zalcberg JR, Moore MJ, Zhu L, Jonker DJ. Vickers MM, et al. Among authors: shapiro jd. Ann Oncol. 2013 Apr;24(4):953-60. doi: 10.1093/annonc/mds577. Epub 2012 Nov 8. Ann Oncol. 2013. PMID: 23144444 Free article. Clinical Trial.
Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.
Au HJ, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ. Au HJ, et al. Among authors: shapiro jd. J Clin Oncol. 2009 Apr 10;27(11):1822-8. doi: 10.1200/JCO.2008.19.6048. Epub 2009 Mar 9. J Clin Oncol. 2009. PMID: 19273701 Clinical Trial.
Management of advanced gastric cancer.
Price TJ, Shapiro JD, Segelov E, Karapetis CS, Pavlakis N, Van Cutsem E, Shah MA, Kang YK, Tebbutt NC. Price TJ, et al. Among authors: shapiro jd. Expert Rev Gastroenterol Hepatol. 2012 Apr;6(2):199-208; quiz 209. doi: 10.1586/egh.11.103. Expert Rev Gastroenterol Hepatol. 2012. PMID: 22375525 Review.
Current opinion on optimal treatment for colorectal cancer.
Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, Karapetis CS, Pavlakis N, Sobrero AF, Cunningham D, Shapiro JD. Price TJ, et al. Among authors: shapiro jd. Expert Rev Anticancer Ther. 2013 May;13(5):597-611. doi: 10.1586/era.13.37. Expert Rev Anticancer Ther. 2013. PMID: 23617351 Review.
65 results